CARBOPLATINE HOSPIRA 10 mg/ml, solution injectable pour perfusion, Alunbrig 30 mg film-coated tablets, Alunbrig 180 mg film-coated tablets, Pemetrexed Viatris 25 mg/ml, solution à diluer pour perfusion
IFCT-2101
Phase 2 small_molecule active
Quick answer
CARBOPLATINE HOSPIRA 10 mg/ml, solution injectable pour perfusion, Alunbrig 30 mg film-coated tablets, Alunbrig 180 mg film-coated tablets, Pemetrexed Viatris 25 mg/ml, solution à diluer pour perfusion for advanced ALK-positive non-small cell lung cancer is a Phase 2 program (small_molecule) at CERO THERAPEUTICS HOLDINGS, INC. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- CERO THERAPEUTICS HOLDINGS, INC.
- Indication
- advanced ALK-positive non-small cell lung cancer
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active